TENX — Tenax Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Tenax Therapeutics Inc - Received A Notice Of Allowance From Uspto For Its Patent Application With Claims Covering Use Of Tnx-103, Oral Levosimendan
Tenax Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Tenax Therapeutics Provides 2023 Business Update
Tenax Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Tenax Therapeutics Receives Notice Of Delisting Or Failure From Nasdaq
Tenax Therapeutics Inc expected to post a loss of $1.94 a share - Earnings Preview
Brief: Tenax Announces Issuance Of U.S. Patent Covering Use Of Iv Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (Ph-Hfpef)
Brief: Tenax Therapeutics Announces Pricing Of Approximately $15.6 Million Public Offering
U.S. STOCKS ON THE MOVE-Arrow Electronics, fintechs, Amazon.com,
U.S. STOCKS ON THE MOVE-Aptiv, NRx Pharma, Becton Dickinson
U.S. STOCKS ON THE MOVE-Tenax Therapeutics, Pinterest, Harley-Davidson
Tenax Therapeutics soars on U.S. patent for pulmonary hypertension drug
Brief: Tenax Granted Notice Of Allowance For U.S. Patent Application Pulmonary Hypertension Drug
Brief: Tenax Therapeutics Inc Files Prospectus For Offering Of Up To 5.8 Million Shares Of Our Common Stock
Brief: Tenax Therapeutics Inc Receives Notification From Nasdaq For Regaining Compliance
Brief: Tenax Therapeutics Announces Reverse Stock Split
U.S. STOCKS ON THE MOVE-Microsoft, Salesforce, China ADRs
Tenax Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Positive Data Presented At Hfsa Annual Meeting Demonstrate Effects Of Oral Levosimendan In Patients With Pulmonary Hypertension And Heart Failure With Preserved Ejection Fraction (Ph-Hfpef)